The Diabetes Drug That Might Stop Your Gout Flares

Here’s something that surprised me when I first heard it: certain diabetes drugs can reduce gout attacks by roughly 30-40%—separate from any blood sugar effect.

Not a tiny pilot study nobody can replicate. Large trials, thousands of patients, consistent numbers across different drugs in the class. If you’ve got gout plus diabetes or heart problems, this actually matters for your treatment plan.

What Are SGLT-2 Inhibitors?

SGLT-2 inhibitors (short for sodium-glucose cotransporter-2 inhibitors) are a class of prescription drugs originally designed to lower blood sugar in people with type 2 diabetes. Brand names you might recognize: Jardiance (empagliflozin), Farxiga (dapagliflozin), Invokana (canagliflozin), and combination pills like Xigduo XR (dapagliflozin plus metformin).

They work by forcing your kidneys to flush excess glucose out through your urine. About 90% of the glucose your kidneys filter normally gets reabsorbed back into your bloodstream. SGLT-2 inhibitors block that reabsorption, so sugar leaves your body instead of recirculating. Simple mechanism, and for blood sugar control, it works well.

But the gout connection came as a total surprise to most researchers.

How SGLT-2 Inhibitors Actually Lower Uric Acid

To understand why these drugs help with gout, you need to know a bit about how your kidneys handle uric acid. About two-thirds of the uric acid your body produces gets excreted through your kidneys. The rest leaves through your digestive tract.

Here’s where it gets interesting. In your kidneys, uric acid gets filtered at the glomerulus, but then about 90% of it gets reabsorbed back into your blood through a transporter protein called URAT1 (urate anion exchanger 1). It’s a similar setup to glucose: your body tries to hold onto things it thinks are valuable.

When SGLT-2 inhibitors increase the amount of glucose flowing through your kidney tubules, that extra glucose appears to compete with uric acid for reabsorption through another transporter called GLUT9b. Think of it like a crowded doorway: when glucose is flooding through, uric acid gets pushed out into the urine instead of being pulled back into your bloodstream. [1]

But that’s not the whole story. Research from 2025 showed that SGLT-2 inhibitors also reduce the expression of URAT1 itself, meaning they directly dial down the kidney’s ability to reclaim uric acid. There’s also emerging evidence that these drugs may dampen xanthine oxidase activity through the SIRT-1 signaling pathway, which could reduce how much uric acid your body produces in the first place. [2]

The result? Less uric acid in your blood, which means fewer opportunities for those needle-like crystals to form in your joints.

The Gout Connection

Here’s the deal: people taking SGLT-2 inhibitors for diabetes started showing up in clinic data with significantly fewer gout attacks. Not one small trial—multiple large randomized controlled trials, some tracking patients for years.

The numbers are striking. A 2024 target trial emulation study published in JAMA Network Open compared over 200,000 patients with type 2 diabetes who were either started on an SGLT-2 inhibitor or a sulfonylurea (a different class of diabetes drug). The SGLT-2 inhibitor group had a 38% lower risk of developing gout and a 33% lower rate of recurrent gout flares compared to the sulfonylurea group. That translated to 3 fewer new gout cases and 21 fewer recurrent flares per 1,000 person-years. [2]

How does it work? By increasing urinary glucose excretion, SGLT-2 inhibitors ramp up uric acid excretion through the same transporter proteins. Less uric acid sitting in your bloodstream means fewer crystals forming in your joints. [1]

The EMPEROR-Reduced trial, which studied empagliflozin in heart failure patients, found that the drug reduced serum uric acid by 1.12 mg/dL compared to placebo. It also cut the risk of gout flares, gouty arthritis, or the need to start gout therapy by 32%. [3]

A 2025 meta-analysis of 51 randomized controlled trials, published in Frontiers in Pharmacology, confirmed the class-wide effect. Across all SGLT-2 inhibitors, serum uric acid dropped by an average of 32.14 µmol/L (about 0.54 mg/dL) compared to placebo. Interestingly, this same analysis found no statistically significant difference in gout incidence between SGLT-2 inhibitor users and placebo groups, which suggests the uric acid reduction alone may not fully explain how these drugs affect gout risk. [5]

Which SGLT-2 Inhibitor Works Best for Uric Acid?

Not all drugs in this class are equal when it comes to lowering uric acid. A 2025 review broke down the uric-acid-lowering performance of each major SGLT-2 inhibitor: [1]

Empagliflozin (Jardiance) came out on top. In the EMPEROR-Reduced trial, it lowered serum uric acid by 1.12 mg/dL. In the EMPA-KIDNEY trial, the reduction was more modest at about 0.43 mg/dL, but that trial included patients with significantly reduced kidney function, where the uricosuric effect is known to be weaker. [4]

Dapagliflozin (Farxiga) lowered uric acid by 0.51 to 0.84 mg/dL across various studies. A large population-based cohort study published in Diabetes, Obesity and Metabolism found that dapagliflozin users had a 21% lower risk of developing gout compared to those on other diabetes medications. [6]

Canagliflozin (Invokana) showed reductions of 0.39 to 0.69 mg/dL. Post hoc analyses from the CANVAS trial program found that canagliflozin reduced serum urate by 6.7% compared to placebo, with the effect holding steady over 3.6 years of follow-up. [7]

Ertugliflozin (Steglatro) and sotagliflozin had the smallest effects, with reductions of only 0.23 to 0.26 mg/dL. If uric acid reduction is a priority, empagliflozin appears to be the strongest performer, though the choice of drug should be based on your overall health picture, not just uric acid numbers.

What This Means for People With Gout

If you have both gout and type 2 diabetes, SGLT-2 inhibitors offer something rare: a single drug that addresses two conditions at once. Beyond lowering uric acid, these drugs also reduce cardiovascular events, protect kidney function, and promote modest weight loss. For people with gout, who already face elevated risks of heart disease and kidney problems, that’s a meaningful combination.

But context matters. If your kidney function is significantly reduced (eGFR below 30 mL/min/1.73 m²), the uric-acid-lowering effect shrinks considerably. The EMPA-KIDNEY trial showed that while empagliflozin still lowered uric acid in patients with chronic kidney disease, the effect was smaller and did not translate into a statistically significant reduction in gout events. [4]

It’s also worth noting that SGLT-2 inhibitors shouldn’t replace your current gout treatment. If you’re already on allopurinol or febuxostat, keep taking it. Think of SGLT-2 inhibitors as a potential bonus layer of protection, not a substitute for proven urate-lowering therapy. For a deeper look at how allopurinol works and why it remains the gold standard, check out our guide on allopurinol’s effects beyond gout.

If you’re taking blood pressure medications alongside gout treatment, that’s another piece of the puzzle. Some blood pressure drugs raise uric acid, which could undermine the benefits you’re getting from an SGLT-2 inhibitor. Our article on blood pressure pills and gout covers which medications to watch out for, and our deep dive on how valsartan affects uric acid goes into the specifics of one common blood pressure drug.

Should You Ask Your Doctor About SGLT-2 Inhibitors?

Here’s the honest answer: maybe. If you have both type 2 diabetes and gout, this class of drugs might be worth discussing with whoever manages your diabetes or heart health. Some cardiologists are already prescribing them specifically for cardiovascular benefits, and the gout reduction is a secondary win.

But—and this matters—SGLT-2 inhibitors aren’t right for everyone. They increase the risk of genital infections, can cause dehydration, and in rare cases lead to diabetic ketoacidosis. [8] Your GP or specialist needs to weigh the pros and cons for your specific situation.

If you don’t have diabetes, these aren’t an option. Researchers are studying whether the uric-acid-lowering mechanism could be replicated in a non-diabetes formulation, but nothing exists yet. [1] For now, if you have gout without diabetes, your best path remains standard urate-lowering therapy, diet modifications, and working with your doctor to identify any medications that might be raising your uric acid.

The Bottom Line

SGLT-2 inhibitors aren’t a gout cure. But for the substantial group of people with gout who also have type 2 diabetes or heart disease, they represent one of the most evidence-backed add-ons to standard uric acid treatment we’ve seen in years.

The data is consistent across multiple large trials, the mechanism makes biological sense, and the cardiovascular and kidney benefits make these drugs attractive well beyond their gout-reducing side effect. Worth a conversation with your doctor if you’re in that overlap group.

Frequently Asked Questions

Do SGLT-2 inhibitors interact with gout medications like allopurinol?

No significant negative interactions have been documented between SGLT-2 inhibitors and xanthine oxidase inhibitors (allopurinol, febuxostat). Some early research suggests they may actually work synergistically, meaning the combined effect could be greater than either drug alone. [2] That said, always check with your prescribing doctor before combining or switching medications.

Can I take SGLT-2 inhibitors if I only have gout, not diabetes?

Currently no. These are prescription-only diabetes medications. Taking them without diabetes would also lower your blood sugar unnaturally, which carries real risks. Researchers are exploring whether the uric-acid-lowering mechanism can be isolated into a separate drug, but that’s years away from clinical use. [1]

Will SGLT-2 inhibitors eliminate my gout attacks completely?

No. The 30-40% reduction in flares seen in trials is meaningful, but it means most people still experience attacks. Think of it as an additional layer of protection on top of proven uric acid management (diet, lifestyle, and/or medication), not a replacement for any of those.

Are there side effects I should know about?

Yes. The most common are increased urination and thirst, genital infections (especially yeast infections in women), and dehydration. More serious but rare risks include diabetic ketoacidosis and necrotizing fasciitis of the perineum (Fournier’s gangrene). [8] If you experience fever, genital pain, or unusual fatigue while on these drugs, seek medical attention promptly.

Which SGLT-2 inhibitor should I ask my doctor about?

Empagliflozin (Jardiance) has shown the largest uric acid reductions in clinical trials, followed by dapagliflozin (Farxiga) and canagliflozin (Invokana). But the right choice depends on your full health picture, including kidney function, heart health, insurance coverage, and other medications you’re taking. Your doctor can help you weigh those factors.

Reviewed by the GoutSavvy Editorial Team